We are developing a rich portfolio of immunotherapies for some of the most difficult-to-treat infections. Our mission is to bring these potentially life-saving treatments to patients as quickly as possible.
Humabs BioMed is a private antibody therapeutics biotechnology company based in Switzerland spin-off from the Institute of Biomedical Research (IRB), Bellinzona, with which Humabs has a strong collaborative relationship.
The Company is focused on discovering and developing fully human monoclonal antibodies to treat serious infections. Humabs has proprietary discovery technologies – CellClone – that were utilized successfully to advance from discovery to lead compounds in only a few months. The CellClone technology platforms enable the isolation of antibodies that have passed natural selection by the human immune system in response to infectious diseases and can generally be further developed without extensive lead optimization.
Humabs has a portfolio of more than a dozen immunotherapy product candidates, some addressing large markets and others against orphan diseases, which, while small in terms of patient numbers, have high morbidity and mortality rates.
The Company has partnered several programs with major pharmaceutical companies, and two of these programs are now in clinical development. The Company is internally developing antibodies directed against hepatitis B virus (HBV) and respiratory syncytial virus and metapneumovirus (RSV/MPV). These programs are currently in preclinical development. In collaboration with various public health agencies, Humabs is also developing a portfolio of antibodies against major public health threats, including MERS-CoV, Zika, Dengue, Ebola and Rabies viruses.


Humabs’ three-pronged strategy involves the following:
1) retain and strengthen scientific leadership and grow the pipeline
2) bring development programs to clinical proof of concept and then partner
3) advance the public health portfolio in collaboration with government agencies and other organizations
Humabs’ technology platform has already been successfully validated through two clinical-stage partnered programs.
The Company plans to retain and strengthen its technology leadership by continuing to invest in its platforms and research capabilities, in parallel to growing its internal development pipeline. The Company’s internal skills, access to the Institute for Research in Biomedicine (IRB), along with multiple collaborations with leading scientific groups worldwide, play a critical role in maintaining and expanding Humabs’ scientific leadership.
The funds from partnered programs are being utilized to advance Humabs’ internal pipeline of product candidates and bring them to clinical proof of concept.
Once this is achieved, the programs will be partnered with major biopharmaceutical companies for further development and commercialization. This strategy will enable Humabs to focus on its areas of strength – discovery and early-stage development – and participate in the future upside potential of its programs. In collaboration with public health institutions and supported by non-dilutive funding, Humabs is also advancing a portfolio of product candidates that address major public health threats. This includes developing new therapies to treat infectious diseases in developing countries, as well as growing global public health concerns.